EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS)

Isabelle Borget, Mehdi Benchaib, Philippine Poignant, Laetitia Rey, Gerard Harty, Vivek Chaudhari, Thomas D'hooghe, Juan-Enrique Schwarze, Isabelle Cedrin Durnerin, Claudia Roeder, Michael Grynberg

Gynecologic and Obstetric Investigation · 19.11.2024 · 90 (3) · 211-225

DOI: 10.1159/000542074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gynecologic and Obstetric Investigation, online erschienen am 19.11.2024. Verfasst von Isabelle Borget und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France. Hauptthemen laut MEDLINE: Ovulation Induction, Reproductive Techniques, Assisted, Gonadotropins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Various gonadotropins are used for ovarian stimulation (OS). This study investigated the cost-effectiveness of different gonadotropins based on real-world data from the French National Health Database (SNDS) over a 7-year follow-up of assisted reproductive technology (ART) treatments.

Design

Cost-effectiveness analysis of different gonadotropins based on real-world data from the SNDS was conducted.

Participants

Women from SNDS undergoing OS leading to oocyte pick-up registered between January 31, 2013, and December 31, 2018 (N = 245,534 stimulations), and receiving either recombinant human follicle stimulating hormone (r-hFSH alfa originator; 110,439), its biosimilars (12,287), or urinaries (mainly highly purified human menopausal gonadotropin [HP-hMG; 65,654] and marginally highly purified urinary-human follicle stimulating hormone [7,821]) were included (follow-up: December 31, 2019). Settings and Methods: Clinical inputs for this model, including live birth (LB) and cumulative LB (CLB) were calculated from data as published in [Best Pract Res Clin Obstet Gynaecol. 2023;88:102308]. A decision-tree model was developed comprising pregnancy and live birth rate (LBR) states for a complete ART cycle, including one fresh and ≤4 frozen/thawed embryo transfers and related costs. Cost inputs included those of drugs, ART procedure, pregnancy and delivery, and adverse events. Cost per LB and CLB and incremental cost-effectiveness ratio (ICER) were assessed. Robustness of results was determined by comprehensive sensitivity analyses.

Results

Overall, r-hFSH alfa originator was found to be associated with a lower cost per LB and per CLB (cost per LB: EUR 26,010; CLB: EUR 22,278) versus its biosimilars (cost per LB: EUR 28,037; CLB: EUR 23,807) and versus urinaries (cost per LB: EUR 26,636; CLB: EUR 23,335). Calculated ICERs with r-hFSH alfa for LB were EUR 5,538 and EUR 14,090, whereas for CLB were EUR 1,945 and EUR 13,742 versus biosimilars and urinaries, respectively. Cost-effectiveness acceptability curve showed that in a majority of iterations, r-hFSH alfa originator had a probability of being cost-effective at a hypothetical threshold of EUR 20,000/LB. Sensitivity analyses showed that the most important variable impacting the outcome in fresh transfers was the probability of birth for biosimilars and the probability of pregnancy for urinaries, while for cumulative transfers, it was the probability of pregnancy for biosimilars and the probability of birth for urinaries.

Limitations

As the clinical data were obtained from a non-interventional study and not a randomized controlled trial, the results may still be susceptible to residual confounding or other biases. Conclusions: r-hFSH alfa originator is cost-effective compared to its biosimilars and to urinaries (mainly HP-hMG) and is associated with a lower cost per LB compared to these gonadotropins, where the main driver is the higher LB efficacy rate achieved with it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovulation InductionReproductive Techniques, AssistedGonadotropinsHumansFemaleCost-Benefit AnalysisFrancePregnancyAdultDatabases, FactualPregnancy RateMenotropinsFollicle Stimulating Hormone, HumanCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost per live birthIncremental cost-effectiveness ratioLive birthReal-world dataRecombinant human follicle stimulating hormone

Substanzen

GonadotropinsMenotropinsFollicle Stimulating Hormone, Human

Autor:innen und Institutionen

  • Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
  • Oncostat - U1018, Inserm, Paris-Saclay University, "Ligue Contre le Cancer" Labeled Team, Villejuif, France.
  • Service de médecine de la reproduction et préservation de la fertilité - CECOS, Hospices Civils de Lyon, Bron, France.
  • Faculté de médecine Lyon Est, Université Claude Bernard Lyon 1, Lyon, France.
  • LBBE CNRS, Villeurbanne, France.
  • IQVIA, Paris, France.

Zitieren

APA

Borget, I., Benchaib, M., Poignant, P., Rey, L., Harty, G., Chaudhari, V., D'hooghe, T., Schwarze, J. E., Cedrin Durnerin, I., Roeder, C., & Grynberg, M. (2024). A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecologic and Obstetric Investigation, 90(3), 211-225. https://doi.org/10.1159/000542074

Vancouver

Borget I, Benchaib M, Poignant P, Rey L, Harty G, Chaudhari V, et al. A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). Gynecologic and Obstetric Investigation. 2024;90(3):211-225. doi:10.1159/000542074

BibTeX
@article{Borget2024,
  author = {Borget, Isabelle and Benchaib, Mehdi and Poignant, Philippine and Rey, Laetitia and Harty, Gerard and Chaudhari, Vivek and D'hooghe, Thomas and Schwarze, Juan-Enrique and Cedrin Durnerin, Isabelle and Roeder, Claudia and Grynberg, Michael},
  title = {A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS)},
  journal = {Gynecologic and Obstetric Investigation},
  year = {2024},
  volume = {90},
  number = {3},
  pages = {211--225},
  doi = {10.1159/000542074}
}
Kostenlos starten →